Secondary Hyperparathyroidism (SHPT) Treatment Market

Secondary Hyperparathyroidism (SHPT) Treatment Market Outlook 2032

The global secondary hyperparathyroidism (SHPT) treatment market size was USD 7.4 Billion in 2023 and is projected to reach USD 16.4 Billion by 2032, expanding at a CAGR of 9.4% during 2024–2032. The market growth is attributed to the increasing demand for innovative therapeutic solutions and advancements in medical technology, including SHPT treatment.

Increasing awareness of the health risks associated with secondary hyperparathyroidism (SHPT) is expected to further boost the SHPT treatment market during the forecast period. This market growth is driven by a growing consumer base seeking effective therapies for conditions that increase the risk of SHPT. Furthermore, the growing geriatric population across the globe is vulnerable to developing SHPT, due to age-related changes in renal function and bone metabolism, further boost the demand for efficient secondary hyperparathyroidism treatment solutions.

• According to a report by WHO, the global population of people aged 60 years and above is expected to double to 2.1 billion by 2050.

Get Free Sample Report

Impact of Artificial Intelligence (AI) in the Secondary Hyperparathyroidism (SHPT) Treatment Market

The use of artificial intelligence is likely to boost the secondary hyperparathyroidism (SHPT) treatment market. AI-powered algorithms analyze vast amounts of patient data to identify patterns and personalize treatment regimens based on individual patient profiles. Additionally, AI-powered imaging technologies enhance the accuracy and efficiency of diagnostic procedures, enabling early detection of SHPT and other related conditions.

Secondary Hyperparathyroidism (SHPT) Treatment Market Dynamics

Get Free Sample Report

Major Drivers

Increasing prevalence of chronic kidney disease (CKD) is anticipated to drive the market during the forecast period. CKD is an associated risk factor for the development of SHPT, due to alterations in mineral and bone metabolism. The high demand for effective SHPT treatments correlates with the global rise in CKD prevalence, notably among the elderly, diabetic, and hypertensive populations. Moreover, the rising pool of patients requiring treatment for SHPT is expected to boost the market in the coming years.

• According to a report published by the National Library of Medicine in March 2022, around 10% of the global population is affected by chronic kidney disease in progressive condition.

Existing Restraints

High cost of treatment options is expected to hinder the market during the forecast period. The management of SHPT often involves the use of expensive medications, such as calcimimetics and vitamin D analogs. Moreover, the limited availability of advanced healthcare infrastructure and expertise in many regions, especially rural and underserved areas further hinders the market.

Emerging Opportunities

­Growing investment in research and development (R&D) is expected to create immense opportunities for the players competing in the market in the coming years. Pharmaceutical companies and academic institutions are investing heavily aiming to address unmet medical needs and improve patient outcomes. Moreover, the development of biomarkers and genetic testing tools facilitates the early detection of SHPT risk factors is expected to propel the market during the forecast period.

Scope of the Secondary Hyperparathyroidism (SHPT) Treatment Market Report

The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics are included in the report.

Secondary Hyperparathyroidism (SHPT) Treatment Market Segment Insights

Drug Class Segment Analysis

Based on drug class, the secondary hyperparathyroidism (SHPT) treatment market is divided into vitamin D analogues, phosphate binders, and calcimimetics. The calcimimetics segment held a major share of the market in 2023, due to their growing adoption for its favorable safety profile and ease of administration.

Calcimimetics is efficient in managing hyperparathyroidism by directly targeting the calcium-sensing receptors on the parathyroid glands to reduce parathyroid hormone (PTH) levels. Moreover, the increasing research and development activities focused on optimizing calcimimetic therapy further bolstered the segment.

The phosphate segment is expected to expand at a significant growth rate in the coming years, as they are widely used for treating the high prevalence of hyperphosphatemia in CKD patients. Furthermore, ongoing research efforts aimed at developing novel phosphate binders with enhanced efficacy and tolerability profiles are likely to further propel the segment in the coming years.

Distribution Channel Segment Analysis

On the basis of distribution channel, the global market is segregated into online channel, hospitals & retail pharmacies, online channels, and others. The hospitals & retail pharmacies segment held a large market share in 2023, due to the widespread availability of SHPT treatment medications and medical devices in these types of pharmacies.

These traditional distribution channels offer convenience and accessibility to patients seeking SHPT treatment. Moreover, these pharmacies ensure continuity of treatment and adherence to prescribed regimens among patients through dispensing maintenance medications for SHPT, thereby boosting the segment. 

The online channels segment is expected to hold a substantial market revenue during the projection period, owing to the growing number of patients turning to e-commerce platforms to find solutions for SHPT treatment. Online channels provide patients with the option to purchase medications and medical supplies from the comfort of their homes. Furthermore, e-pharmacy enables patients to compare prices, read product reviews, and access information about SHPT treatment options which further contributes to boosting the segment during the forecast period.

Get Free Sample Report

Regional Outlook

In terms of region, the global secondary hyperparathyroidism (SHPT) treatment market is classified as Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa. North America held a major market share in 2023, due to a large population requiring treatment for SHPT as a complication of this condition. Additionally, the presence of the older population in this region contributes to the rising incidence of SHPT, further fueling the market.

• As per the report published by the United States Census Bureau on May 25, 2023, an estimated 55,892,014 people aged 65 and over living in the US as of the 2021 American Community Survey.

The market in Asia Pacific is projected to grow at a significant pace in the years to come, owing to the growing prevalence of CKD. Factors, such as sedentary lifestyles and the growing burden of non-communicable diseases contribute large population requiring treatment for SHPT. Moreover, the rising healthcare expenditure and increasing adoption of advanced medical technologies, including advanced SHPT further boost the market during the forecast period.

Get Free Sample Report

Segments

The secondary hyperparathyroidism (SHPT) treatment market has been segmented on the basis of

Drug Class

• Vitamin D Analogues
• Phosphate Binders
• Calcimimetics

Distribution Channel

• Online Channel
• Hospitals & Retail Pharmacies
• Online Channels
• Others

Region

• Asia Pacific
• North America
• Latin America
• Europe
• Middle East & Africa

Key Players

• Amgen Inc
• Pfizer Inc
• F. Hoffmann-La Roche Ltd
• AbbVie Inc
• Sanofi
• GSK plc
• Novartis AG
• Teva Pharmaceutical Industries Ltd
• Kyowa Kirin Co., Ltd
• Bayer AG
• AstraZeneca
• Pathalys Pharma

Competitive Landscape

Key players competing in the global secondary hyperparathyroidism (SHPT) treatment market are Amgen Inc; F. Hoffmann-La Roche Ltd; AbbVie Inc; Pfizer Inc; Sanofi; GSK plc; Novartis AG; Teva Pharmaceutical Industries Ltd; Kyowa Kirin Co., Ltd; Bayer AG; AstraZeneca; and Pathalys Pharma.

These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base globally. For instances,

• On May 31, 2023, Pathalys Pharma, Inc, a biopharmaceutical company, Pathalys Pharma, Inc., a biopharmaceutical company, and Launch Therapeutics announced the enrollment of the first patient, marking the initiation of the PATH clinical program. The program comprises two identical phase 3 trials aimed at evaluating the efficacy of upacicalcet in treating secondary hyperparathyroidism (SHPT) in end-stage kidney disease (ESKD) patients undergoing hemodialysis.